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Background: Clinical decision-making for patients with stage I lung cancer is complex. It involves multiple
options (lobectomy, segmentectomy, wedge, Stereotactic Body Radiotherapy, thermal ablation), weighing
multiple outcomes (e.g., short-, intermediate-, long-term) and multiple aspects of each (e.g., magnitude of a
difference, the degree of confidence in the evidence, and the applicability to the patient and setting at hand).
A structure is needed to summarize the relevant evidence for an individual patient and to identify which
outcomes have the greatest impact on the decision-making.
Methods: Based on a systematic review from 2000–2021, evidence regarding relevant outcomes was
assembled, with attention to aspects of applicability, uncertainty and effect modifiers. A framework was
developed to present this information a format that enhances decision-making at the point of care for
individual patients.
Results: While patients often cross over several boundaries, the evidence fits into categories of healthy
patients, compromised patients, and favorable tumors. In healthy patients with typical (i.e., solid spiculated)
lung cancers, the impact on long-term outcomes is the major driver of treatment selection. This is only
slightly ameliorated in older patients. In compromised patients increasing frailty accentuates short-term
differences and diminishes long-term differences especially when considering non-surgical vs. surgical
approaches; nuances of patient selection (technical treatment feasibility, anticipated risk of acute toxicity,
delayed toxicity, and long-term outcomes) as well as patient values are increasingly influential. Favorable
(less-aggressive) tumors generally have good long-term outcomes regardless of the treatment approach.
Discussion: A framework is provided that organizes the evidence and identifies the major drivers of
decision-making for an individual patient. This facilitates blending available evidence and clinical judgment
in a flexible, nuanced manner that enhances individualized clinical care.
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Introduction

Methods

Early-stage non-small cell lung cancer (NSCLC) is
changing. Increased use of CT scanning is detecting smaller
and more indolent tumors (1-4). The average age of patients
diagnosed and treated is increasing, as is the proportion
with co-morbidities (2,3,5). Possible reasons include
increasing general life expectancy, decreasing treatmentrelated toxicities, and increasing willingness to be treated.
Treatment options for stage I NSCLC have evolved.
This includes minimally invasive surgical techniques [e.g.,
video-assisted thoracic surgery (VATS)], less extensive
resection, and non-surgical treatments like stereotactic body
radiotherapy (SBRT) and thermal ablation. It is important
to appropriately match the treatment to the patient and
tumor, avoiding both overtreatment and undertreatment.
Decision-making regarding stage I NSCLC has
become complex. There are several treatment options and
a spectrum of patients and tumors. There are multiple
aspects to consider, e.g., short-term impact and longterm outcomes. Weighing various considerations is what
constitutes clinical judgement. Furthermore, the likelihood
and severity of various potential outcomes must be
assessed for an individual patient and setting—considering
applicability and ambiguities of the available evidence as
well as patients’ values and preferences.
Our decisions should be evidence-based, but this is
challenging with stage I NSCLC. The spectrum of patients,
tumors, treatments and outcomes is wide. The available
evidence is extensive, but confusing and confounded. Often
outcomes and cohorts aren’t clearly defined, multiple
sources of uncertainty exist, and nuances of patients, tumors
and settings affect the applicability.
We undertook to sift through the evidence, critically
addressing confounders and limitations, seeking to provide
as much clarity and confidence in applicability in various
circumstances as possible. Furthermore, this initiative aims
to assemble the evidence in a concise format that enhances
clinicians’ real-life decision-making with individual
patients. The project consists of 4 publications: part 1 (this
paper) concisely summarizes the evidence and provides a
framework to guide clinical decision-making, part 2 reviews
the body of evidence regarding surgery in generally healthy
patients (6), part 3 addresses specific patients and tumors (7),
part 4 focuses on evidence regarding SBRT and ablation (8).
We present the following article in accordance with the
PRISMA reporting checklist (available at https://jtd.
amegroups.com/article/view/10.21037/jtd-21-1823/rc).

Overarching strategy
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The goal of this initiative is to summarize and organize data
that is relevant to decision-making for individual patients,
recognizing that there are many patient-related, tumorrelated, technical/therapy-related and local environmentrelated factors and values that bear upon the decision for a
particular patient. Clinical judgment involves weighing an
aggregate of considerations; the impact of various factors,
their relevance to the patient and situation at hand, and
the degree of uncertainty about these aspects. We avoid
defining a generally right answer, aiming instead to assess
relevant evidence, ambiguity and uncertainty in a manner
that provides a scientific foundation with flexibility to
facilitate application to individual patients.
We sought to be as inclusive as possible in gathering
relevant data, recognizing that indirect data can be useful
when direct data is limited. We also sought to be a critical as
possible in assessing the degree of confidence that observed
outcomes can be attributed to a treatment intervention as
opposed to confounding factors. Additionally, we critically
considered nuances of the patients, tumors, settings and
interventions to gain insight into applicability and/or
limitations of the observations.
Study panel
A study panel was assembled with representatives of
relevant specialties, all without relevant conflicts of interest.
Most members have a long history of close collaboration
and joint decision-making for stage I NSCLC. There was
no funding source.
Key questions
Key study questions are described below and listed in
Appendix 1-1.
Patients and tumors
The focus of the project is patients with stage cI NSCLC—
ideally cIA tumors (i.e., T1N0M0 (≤3 cm)]. To facilitate
contemporary applicability and consistency, we use the
current 8th edition TNM classification (9) throughout
(translating earlier TNM definitions into the 8th edition
nomenclature). However, the 8th edition defines size by the
solid (imaging) or invasive (histologic) component, ignoring
the size of a ground glass (GG) or lepidic component.
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Because most studies don’t differentiate total vs. solid/
invasive size, we had to use the reported size—a minor
issue since studies involve predominantly solid tumors. The
consolidation to tumor ratio [CTR, meaning the ratio on
lung windows of the consolidated (dense) to total (GG)
lesion size] provides a surrogate in reports focused on pure
or part-solid GG lung cancers.
While the spectrum of patients constitutes a continuum,
the available evidence falls into 3 categories: generally
healthy patients, older patients, and patients compromised
by severely limited pulmonary reserve.
Interventions and comparators
Curative-intent interventions for stage I include surgical
resection (specifically lobectomy, segmentectomy
and wedge), SBRT (a.k.a. stereotactic ablative body
r a d i o t h e r a p y, S A B R ) a n d t h e r m a l a b l a t i o n ( e . g . ,
radiofrequency, microwave ablation, cryotherapy).
Choice of outcomes of interest
Short-term outcomes deemed most relevant to physicians
and patients are treatment-related mortality, toxicity/
morbidity, pain, and short-term quality-of-life (QOL).
Among long-term outcomes we considered survival,
recurrence, long-term functional capacity and QOL to be
most relevant. We find lung cancer specific survival (LCSS)
to be the cleanest measure of treatment effectiveness.
[Assessments of accuracy have documented that cause of
death in cancer patients is quite reliably assigned (10-12)].
Overall survival (OS) mixes treatment effect and competing
causes of death. We chose freedom-from-recurrence
(FFR) as the best measure of recurrence. Disease-free
survival (DFS) or recurrence-free survival (RFS) obscures
assessment because recurrence and competing deaths
are combined. We find it inappropriate to consider any
death as probably due to cancer in a context that includes
compromised patients and favorable tumors.
Evidence assessment
Literature search and study selection
We performed a systematic search of English literature
in PubMed from 2000–2021 according to standards (13).
Several searches were conducted, reflecting the patients,
tumors, interventions, comparators and outcomes
encompassed by the project. Additionally, the reference
lists of identified papers, especially systematic reviews, were
scrutinized. Details of the search, review and selection
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process are provided in Appendix 1-2.
Studies were selected if they provided evidence relevant
to the primary and secondary questions, focusing on
randomized controlled trials (RCTs) and non-randomized
comparisons (NRCs). NRCs were required to have adjusted
for confounders and have ≥50 patients per arm (reflecting
concern about the reliability of adjustment for multiple
confounders in smaller studies). Details of inclusion and
exclusion criteria for specific evidence tables are listed in table
legends in the Part 2–4 papers (6-8). Studies identified by the
search were reviewed independently by 2 authors; all studies
that contained data relevant to the outcomes of interest and
criteria just described and in each table were included.
Data abstraction
Data was abstracted by one panelist and reviewed by others.
FCD and UK cross-checked all table entries. We abstracted
reported data without imputation for missing data or
re-analysis for missing calculations (e.g., hazard ratios,
statistical significance).
Assessment of confounders and confidence in
attribution of cause and effect
In any complex area multiple factors are at play. It is easy to
mistakenly attribute an observation to the intervention of
interest; accurate assessment requires critical evaluation of
all potential alternative explanations. RCTs (ideally) evenly
distribute all known and unknown confounders between
the arms; however, few RCTs are available addressing the
patients, tumors and treatments in question. To be useful,
NRCs must disentangle the impact of confounders from the
intervention of interest (14).
Major potential confounding factors were identified at the
outset. These included non-medical patient related factors
(e.g., age, education, socioeconomic status), medical patientrelated factors [e.g., comorbidities, performance status (PS),
severity of comorbidities], discrepancies in stage classification
(e.g., node assessment), study era (treatments skewed towards
different time periods), facility quality (treatments skewed
towards particular facilities), discrepancy in treatment quality
(e.g., margin adequacy, adjuvant therapy), favorable tumor
selection (e.g., smaller, GG or less metabolically active
tumors, conversion to lobectomy if upstaging is suspected/
encountered). Many confounders are inter-related.
Several statistical methods of adjustment for multiple
factors are available, such as multivariable regression (e.g.,
Cox proportional hazards model) and propensity scoring
(e.g., propensity score adjustment, propensity matching,
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stratification and inverse weighting). These have strengths
and weaknesses that can have greater or limited impact
depending on the nature of the data, outcomes and question
of interest. Most important, however, is which and how
many potential confounders are actually accounted for. In
fact, a prerequisite for propensity scoring is the inclusion of
all relevant factors (15,16); however, this is widely ignored.
Overall risk of bias in relevant NRCs was assessed using
a general tool (17) and a tool developed to provide a more
detailed assessment of the identified domains of potential
confounders relevant to stage I lung cancer. Two reviewers
rated each domain in each study and intervention (details
provided elsewhere; see app. 2-1 of Part 2) (6).
Interpretation of available evidence
Our approach to interpretation of evidence was to focus
on understanding for which patients and situations the
evidence is stronger or weaker, instead of seeking a single
right answer for most patients. The summary assessments
provided in this paper of various factors involved in clinical
decisions for stage I patients are based on a detailed look
at the available evidence (see Part 2–4 papers) (6-8). This
involves thoughtfully organized tables, structured to
facilitate understanding relationships between patient and
tumor characteristics (e.g., age, stage, size), the degree of
confounding and outcomes. This Part 1 paper assembles
this into a framework to guide decision-making.
Assessment of ambiguity and nuances of applicability
Ambiguity arises from uncertainty to what degree
confounding factors may influence the observed impact,
how well we know which patients, tumors, and settings
the evidence applies to, and the confidence that we can
extrapolate beyond this. Nuances refers to factors that
impact the effect of interventions (e.g., VATS vs. open).
Exploring similarities and differences among studies
(regarding details of the patients, tumors, treatments and
confounders) provides insight. In effect, this combines
traditional evidence-based medicine with the realist
approach to clinical science—asking what works, when, in
which patients and how (18).
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of the available clinical science make this challenging. We
created a framework that allows one to identify and focus
on issues with the most impact in a particular setting. This
is achieved by assessing differences relative to what can be
reasonably considered clinically meaningful (defined in
Table S1-1). Individualization requires an understanding of
the general evidence, as well as the inherent uncertainties
and applicability to a particular patient. Furthermore,
individual patients may value particular outcomes
differently. Conceptually this can be imagined as shifting
the fulcrum to give greater leverage to particular outcomes.
We have categorized the considerations into benefits and
downsides and short-, intermediate and long-term outcomes
(Figure 1). Finally, nuances of patients and treatments that
modify the applicability or outcomes should be kept in
mind during clinical decision-making.
Results
Stepwise approach to individual patients
A stepwise approach promotes efficiency and focus (Table 1).
The available evidence falls into several categories—
identifying which one(s) apply to an individual patient and
tumor is the first step. Assessing the evidence highlights
which outcomes impact decision-making (e.g., consistency of
clinically meaningful differences). Technical considerations
may narrow which treatments are reasonably feasible.
A next step is to gain insight into the patient’s attitudes
about their life at present and the future (what a normal day
is like, what do they enjoy, look forward to). This builds
a relationship and provides a stronger understanding of
values than explicitly asking about quality vs. quantity of
life or short- vs. long-term outcomes (or about treatment
preferences, which may be misinformed).
This framework focuses attention on key outcome
differences among feasible treatment options and streamlines
addressing fears and misinformation. This provides a solid
basis for an effective discussion of tradeoffs and uncertainties,
and ultimately well-founded joint decision-making.
Summary of outcomes in healthy patients

Framework for decision-making
This project aims to provide a framework that facilitates
clinical decision-making, which involves weighing
multiple considerations and applying clinical science to an
individual. The multitude of considerations and vagaries
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Resection extent
In healthy patients contemporary RCTs demonstrate
equivalent perioperative mortality for segmentectomy or
wedge vs. lobectomy (1–4% 90-day mortality) (6). Sublobar
resection doesn’t alter the incidence of major complications
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General Evidence Cohorts:

Healthy patients, Older patients, Compromised patients, Favorable Tumors

Specific Treatments
under Consideration

(Lobe, Segment, Wedge Resection, SBRT, Ablation)

Key Long-Term
(5-year) Outcomes

Key Intermediate

(1-2 year) Outcomes

Key Short-Term
(90-day) Outcomes
Legend

Effect
↑↑↑ 2x meaningful improvement
↑↑ Meaningful improvement
↑ Somewhat better
= Similar
↓ Somewhat worse
↓↓ Meaningful worsening
↓↓↓ 2x meaningful worsening

Fulcrum Position
determined by patient
values and preferences
Confidence in /
Consistency of Data
++++ Very High
+++ High
++ Moderate
+ Low
0 Very Low
Extpol Extrapolation

Nuances

Effect modifiers: Patient, tumor, treatment
aspects that accentuate/diminish outcome
differences (or impact applicability of the
evidence base)

Selection: Key considerations to weigh in
selection of treatment approach

Figure 1 General framework for clinical decision-making.
General framework for decision-making about treatment options in individual patients. Qualitative assessment of the impact of treatment
approaches on various key outcome measures and the confidence in the evidence. Differences are categorized by degree of clinically
meaningful differences (defined in Table S1-1).
Extpol, extrapolation; SBRT, stereotactic body radiotherapy.

Table 1 Stepwise approach to decision-making with individual patients
Steps

Details

Impact

1. Identify relevant category(ies)
of evidence

• Healthy patients, typical solid tumors
• Older patients, typical solid tumors
• Compromised patients, solid tumors
• Favorable tumor characteristics

Assembles general evidence into manageable
moderately homogeneous cohorts
Informs nuances of uncertainty/applicability
of general evidence

2. Assess the relevant evidence

• Magnitude of differences
• Consistency of confidence in the evidence
• Uncertainty
• Applicability

Provides basis for weighing various aspects,
considerations

3. Assess technical issues
(anatomic, physiologic,
specific treatment-related
considerations)

• Ability to carry out treatment options without
compromise

Eliminates unrealistic treatments; informs
nuances of applicability of general evidence

4. Identify what is most
important to the individual
patient (short-, long-term,
benefits, potential harms)

• Identify, address fears
• Correct misinformation/assumptions about outcomes
• Ensure that patient has full perspective (e.g., short-,
mid-, long-term, outcome without treatment)

Establish patient’s state-of-mind, allows
rational evaluation; establishes trust/insight
that allows joint decision-making

5. Individualized treatment
selection

• Focus on considerations with major impact (set aside
those without meaningful impact or not applicable)
• Weigh differences, uncertainties in context of what is
most important to the patient

Provides framework to guide physician and
patient to a well-founded decision
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(5–15% grade ≥3) (6). A significant benefit to VATS
over thoracotomy has been demonstrated extensively for
lobectomy; this also appears true for segmentectomy.
Reasonable extrapolation (direct data being absent) is that
robot-assisted resection yields similar outcomes to VATS.
Pain and impaired QOL is generally resolved by 3 months
after VATS resection (see Tabs. 6,7 and Fig. 1 of Part 2) (6).
Adjusted NRCs with high confidence that outcomes are
attributable to the treatment demonstrate worse OS for
segmentectomy or wedge resection than lobectomy (see
Tabs. 1,2,3 and Figs. S2-1,S2-2,S2-3 of Part 2) (6). Multiple
NRCs (with greater residual confounding) mostly favor
lobectomy; most clearly for OS and LCSS for wedge, less
so for segmentectomy vs. lobectomy. It is unclear if lesser
resection increases recurrence risk (due to low locoregional
recurrence rates, few NRCs, low confidence that results
reflect resection extent; see Tab. 4 of Part 2) (6). We await
mature results from 2 RCTs; present aggregate evidence
indicates meaningfully worse long-term outcomes after
segmentectomy or wedge resection than lobectomy in
healthy patients.
VATS resection has little long-term impact on QOL,
but open resection persistently impairs QOL. The impact
of sublobar resection is unclear due to confounding
by VATS/open approach (see Tabs. 6,7 of Part 2) (6).
Pulmonary function tests (PFTs) aren’t meaningfully better
after segmentectomy (especially multi-segmentectomy)
than lobectomy in healthy patients, but might diminish
a subjective increase in dyspnea sometimes noted after
lobectomy (see Tab. 5 of Part 2) (6).
Evidence suggests no meaningful differences in short-,
intermediate- or long-term outcomes for a “lobe-like”
multi-segmentectomy (e.g., lingulectomy or left upper
division resection) vs. lobectomy. Locoregional recurrence
rates are ~25% for margins of ≤1 cm and ~10% with larger
margins, with generally similar findings for a margin/tumor
size ratio of <1 vs. ≥1 (see Tabs. 8,9 of Part 2) (6). Worse
long-term outcomes are reported when a microscopic
finding of “spread through air spaces” (STAS) is present
(especially after sublobar resection); this is confounded
because STAS is associated with many negative prognostic
factors (see Tabs. 10,11 of Part 2) (6). Whether converting
to a lobectomy mitigates the impact of STAS is unclear.
SBRT/ablation vs. surgery in healthy patients
Short-term mortality is ~1% better after SBRT vs. surgery (8).
Grade ≥3 toxicity after SBRT is low initially, but is noted
in ~10–20% by 2 years (6). Comparing across studies,
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average QOL is clearly better after SBRT than surgery,
most markedly in the short-term; also long-term after open
resection (less so after VATS; see Tabs. 6,7 of Part 2 and
Tab. 4 of Part 4) (6,8). On average, PFTs are minimally
decreased after SBRT/ablation; differences between SBRT/
ablation vs. surgery appear to be clinically relevant only vs.
lobectomy. However, 20–40% of SBRT patients experience
a meaningful decline in PFTs after 1–2 years (8).
Limited accrual renders completed RCTs inconclusive.
Results of ongoing RCTs in good-risk and high-risk
patients are anticipated in 2024–2026. Adjusted NRCs quite
consistently report meaningfully worse OS and LCSS for
SBRT/ablation vs. lobectomy or sublobar resection (see
Tabs. 1,2 and Fig. S4-1A,S4-1B of Part 4) (8). Nevertheless,
adjustment for confounders when comparing SBRT/
ablation vs. surgery is inherently challenging.
Decision-making guide in generally healthy patients
Resection extent
Key outcomes
The focus regarding resection extent is on long-term
outcomes (Figure 2A); key points are summarized in Table 2.
Short-term outcomes aren’t meaningfully different. Worse
OS and LCSS is reported, especially for wedge resection vs.
lobectomy (moderate- to low-confidence). QOL is similar;
wedge resection may have a marginal advantage in PFTs and
possibly in ameliorating an increase in dyspnea vs. lobectomy.
Effect modifiers
A sublobar resection margin of ≤1 cm or a margin/
tumor ratio of <1 is associated with a higher loco-regional
recurrence rate (~25% vs. ~10%) and meaningfully worse
RFS (moderate-confidence evidence). STAS correlates with
worse long-term outcomes for both lobectomy and sublobar
resection. Tumor size appears not to modify the difference
between lobectomy vs. lesser resection in OS and LCSS.
PFTs are marginally better after a single segmentectomy
vs. lobectomy. However, “lobe-like” multi-segmentectomy
(e.g., lingulectomy or left upper division resection) provides
no benefit (but also perhaps little long-term downside).
Whether long-term outcome differences for sublobar
resection vs. lobectomy stem from suboptimal node
dissection (and adjuvant chemotherapy) is unclear due to
conflicting evidence.
Selection and patient preferences
The long-term downsides of sublobar resection in healthy
patients are hard to counter by selection factors or
preferences.
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Pain
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ABL
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Effect Conf
↓
+
↓
+
-

Nuances

(pathologic measurement)
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Consistency of Data
++++ Very High
+++ High
++ Moderate
+ Low
0 Very Low
Extpol Extrapolation

th

Tumor size does not affect relative
differences
Short-term outcomes not affected by
resection extent; but marked short-,
mid-term benefits to VATS vs Open
approach (without later tradeoff)

Ed)

NSCLC

Long-Term (5-year) Outcomes
SBRT
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+
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+

(v SL)
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=
0
=
0
=
0
=
0
-

Short-Term (90-day) Outcomes

W

(vs Lobe)
Effect Conf
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↓
+
=/↓ a 0
=/↓ a 0

Differences between Segment vs Lobe
primarily evident for single segment
Likely 2x increased long-term downsides
if M/T ratio <1 or margin <1 cm

SBRT / ABL v
VATS Surgery

Intermediate (1-2 year) Outcomes
SBRT

Seg

Legend

Effect
2x meaningful improvement
Meaningful improvement
Somewhat better
Similar
Somewhat worse
Meaningful worsening
2x meaningful worsening

Generally Healthy Patients, cI (8

SBRT

NSCLC

Long-Term (5-year) Outcomes

Fulcrum Position
determined by patient
values and preferences

W

(vs Seg)
Effect Conf
=
+
=
+
-

B

Ed)

(vs Lobe)
Effect Conf
OS
↓
+
LCSS
↓
+
FFR =/↓ a 0
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Short-Term (90-day) Outcomes
(vs Lobe)
Effect Conf
= ++++
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=a
0
=a
0
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0
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SBRT
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Effect Conf
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↓↓
+
-
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(v SL)
(v SBRT)
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↓
+
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-
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0
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↓
0
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-

Nuances

Legend

↑↑↑
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↑
=
↓
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Effect
2x meaningful improvement
Meaningful improvement
Somewhat better
Similar
Somewhat worse
Meaningful worsening
2x meaningful worsening

Confidence in /
Consistency of Data
++++ Very High
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++ Moderate
+ Low
0 Very Low
Extpol Extrapolation

Short- and intermediate-term benefits of
SBRT/Abl accentuated if resection is open
No difference between peripheral and
central tumors, but toxicity over time with
SBRT for ultra-central tumors is a concern
Tumor size does not affect relative
differences

Figure 2 Decision guide for healthy patients.
(A) Resection extent; (B) SBRT/ablation vs. VATS surgery. Decision guide for a generally healthy patient with a typical stage I lung cancer.
The reference (for improvement or worsening) is the treatment in parentheses.
a

, data not parsed by resection extent (segment vs. wedge).

Δ FEV1, change in FEV1 ≥6 months; Abl, ablation (any thermal technique); Conf, confidence in the evidence; FFR, freedom from
recurrence (only recurrence counts as an event); LCSS, lung cancer specific survival (only a death due to lung cancer counts as an event); L,
lobectomy; LR-FFR, locoregional freedom from recurrence; M/T, margin (distance) to tumor (diameter) ratio; NSCLC, non-small cell lung
cancer; OS, overall survival; QOL, quality of life; SBRT, stereotactic body radiotherapy; SL, sublobar resection; Seg, segmentectomy; VATS,
video-assisted thoracic surgery; W, wedge.
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Table 2 Key takeaway points in healthy patients
• NRCs indicate worse OS/LCSS after segmentectomy/wedge vs. lobectomy
• Short-term outcomes are equivalent after lobectomy, segmentectomy or wedge resection
• Marginally meaningful benefit in PFTs after segmentectomy/wedge vs. lobectomy
• A ≤1 cm sublobar resection margin portends a ~25% loco-regional recurrence rate and meaningfully worse RFS
• SBRT/ablation has a meaningful benefit in short-term outcomes over surgery
• NRCs strongly indicate long-term downsides to SBRT/ablation vs. surgery
• Tumor size appears not to modify long-term differences between lesser resection vs. lobectomy or between SBRT/ablation vs. surgery
NRCs, non-randomized comparisons; OS, overall survival; LCSS, lung cancer specific survival; PFTs, pulmonary function tests; RFS,
recurrence-free survival; SBRT, stereotactic body radiotherapy.

SBRT/ablation vs. surgery
Key outcomes
The focus is balancing short-term benefits of SBRT/
ablation vs. a detriment in OS and LCSS compared with
surgery (high- and low-confidence evidence, Figure 2B).
A small advantage in PFTs for SBRT over lobectomy is
marginally clinically relevant and a weak argument in
treatment selection.
Effect modifiers
Figure 2B addresses VATS resection—deemed to be the
appropriate comparator to SBRT/ablation. Thoracotomy
accentuates the short-term benefits of SBRT/ablation
(Figure S1-1). Short-term outcomes aren’t affected by tumor
location (central/peripheral). Tumor size doesn’t appear to modify
the long-term differences between SBRT/ablation vs. surgery.
Selection and patient preferences
Preferences affect how outcomes are weighed. However, the
long-term downsides to SBRT/ablation vs. VATS resection
are a strong counterweight to the short-term benefits. For
SBRT/ablation vs. open surgery the balance of short- and
intermediate-term benefits vs. long-term downsides is more
even. SBRT/ablation should be avoided for ultra-central
tumors.
Summary of outcomes in older patients
Resection extent
The average life expectancy (~8–20 years) of older lung
cancer patients argues that most should be treated unless
there are severe comorbidities well beyond what is typical
for these patients.
Reported peri-operative mortality among older patients
is consistently low (~2–4%); a slight increase between age
65 and 80 is noted in some series (see Tab. 1 of Part 3) (7).
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Mortality is minimally lower for sublobar resection vs.
lobectomy; in older age cohorts differences are only
slightly increased. Most complications are minor; limited
data suggests that morbidity may be lower after sublobar
resection (see Tab. 1 of Part 3) (7), but a VATS vs. open
approach is likely more impactful.
Reported 5-year OS in older cI patients is reasonable
(40–65%). Several NRCs deemed to have little residual
confounding demonstrate somewhat worse OS/LCSS after
segmentectomy/wedge vs. lobectomy (see Tab. 2 and Fig. S3-2
of Part 3); less well-adjusted NRCs generally support this (7).
Resected older patients are clearly selected, but how is not
well-defined. Most patients had an excellent PS; many had
comorbidities (presumably not severe).
SBRT/ablation vs. surgery
Short-term mortality is 1–4% lower after SBRT than
surgery in patients age >70 (see Fig. 4 of Part 4) (8,19).
This is more pronounced as age increases, and for open
resection. Morbidity is higher initially after surgery, but late
toxicity after SBRT renders the overall incidence relatively
equal after 2 years. Surgery (especially open) impairs QOL;
SBRT/ablation has little impact (see Tabs. 6,7 of Part 2 and
Tab. 4 of Part 4) (6,8).
Several extensively-adjusted NRCs in older patients
demonstrate clinically relevant worse OS/LCSS after SBRT
than surgery; other less well-adjusted studies generally
support this (see Tab. 5 and Fig. S4-2 of Part 4) (8).
Decision guide in older patients
Resection extent
(I) Key outcomes
The focus of decision-making in older patients is on a longterm detriment for sublobar resection (moderate-confidence,
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Aggressive tumors may accentuate long-term
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Key selection factors:
• Patient factors affecting 90-day outcomes;
PS/robustness probably more relevant than age

• Anatomic and technical factors influencing
treatment effectiveness
• Tumor aggressiveness

Figure 3 Decision guide for older patients.
(A) Resection extent; (B) SBRT/ablation vs. VATS surgery. Decision guide for an older patient with a typical stage I lung cancer. The
reference (for improvement or worsening) is the treatment in parentheses.
a

, data not parsed by resection extent (segment vs. wedge).

Δ FEV1, change in FEV1 ≥6 months; Abl, ablation (any thermal technique); Conf, confidence in the evidence; FFR, freedom from
recurrence (only recurrence counts as an event); LCSS, lung cancer specific survival (only a death due to lung cancer counts as an event);
L, lobectomy; LR-FFR, locoregional freedom from recurrence; NSCLC, non-small cell lung cancer; OS, overall survival; PS, performance
status; QOL, quality of life; SBRT, stereotactic body radiotherapy; SL, sublobar resection; Seg, segmentectomy; VATS, video-assisted
thoracic surgery; W, wedge.
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Table 3 Key takeaway points in older patients
• NRCs indicate worse OS/LCSS after segmentectomy/wedge vs. lobectomy
• Marginal benefits in short-term outcomes for segmentectomy/wedge vs. lobectomy
• SBRT/ablation results in short-term benefits and long-term downsides vs. surgery
• Increasing age/frailty accentuates short-term benefits and diminishes long-term downsides of SBRT/ablation vs. surgery
• Selection criteria are not well-defined; factors affecting 90-day outcomes, technical success and tumor aggressiveness are probably
most useful
• Patient preferences affect how outcomes are weighed
NRCs, non-randomized comparisons; OS, overall survival; LCSS, lung cancer specific survival; SBRT, stereotactic body radiotherapy.

Figure 3A); key points are summarized in Table 3. There is
little difference in short- or intermediate-term outcomes
(very low-confidence and indirect evidence). This pattern
is similar to that in generally healthy patients, although the
impact on survival is somewhat attenuated in older patients.
(II) Effect modifiers
Increasing age appears to minimally increase short-term
differences and not to substantially modify long-term
outcome differences; smaller tumor size doesn’t clearly
impact long-term differences. The accentuation of longterm outcome differences associated with a limited resection
margin seen in healthy patients likely applies to older
patients as well, although the impact of oncologic outcomes
is diminished in the face of major competing causes of death.
(III) Selection and patient preferences
The long-term downsides of sublobar resection are hard to
counter by selection factors or preferences.
SBRT/ablation vs. surgery
(I) Key outcomes
This decision in older patients involves balancing short-term
benefits of SBRT against long-term downsides (Figure 3B).
Intermediate-term QOL is similar for SBRT vs. VATS but
SBRT is clearly better vs. open resection (Figure S1-2).
Ablation offers little short-term advantage over sublobar
resection but is associated with a major detriment in OS.
(II) Effect modifiers
Increasing age probably magnifies short-term benefits
and diminishes long-term downsides of SBRT/ablation vs.
VATS resection (moderate-confidence evidence). The same
is probably true with increasing frailty and comorbidities
(speculative extrapolation). Indirectly-supported rationale
suggests that long-term downsides of SBRT/ablation vs.
surgery are accentuated with aggressive tumors (e.g., faster
growth, greater PET-avidity).
(III) Selection and patient preferences
Patient preferences can easily affect the balance when
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considering surgical vs. non-surgical treatment in older
patients.
Characteristics favoring selection for SBRT/ablation
vs. surgery are not well-defined but are probably those
affecting short- and long-term outcome differences.
Summary of outcomes in patients with limited pulmonary
reserve
Resection extent
Most patients with major comorbidities and early-stage
lung cancer die of lung cancer, suggesting that treatment is
generally warranted. The available data focuses on patients
with severely limited pulmonary reserve; extrapolation is
needed for less severe pulmonary compromise or other
major comorbidities.
Limited data suggests little difference in short-term
outcomes between segmentectomy vs. lobectomy. However,
while post-operative morbidity and mortality increases
with decreasing pulmonary reserve, this is markedly
ameliorated by VATS (see Fig. 3 of Part 3) (7). Thirtyday mortality after lobectomy in patients below criteria
cited as contraindications to surgery is 2–3% for VATS
and 3–8% for thoracotomy; pulmonary complication rates
are ~10–20% for VATS vs. ~20–40% for thoracotomy (see
Tab. 3 and Fig. 3 of Part 3) (7).
Lobectomy has less impact on PFTs in patients with
severely limited pulmonary reserve, and in a substantial
proportion FEV1 is unchanged or even improved. Whether
sublobar resection provides a functional benefit over
lobectomy is unclear. Limited data suggests resection has
little average impact on QOL in patients with limited
pulmonary reserve—some are better, some worse and many
are unchanged. A QOL benefit for lesser resection vs.
lobectomy has not been demonstrated, but data is limited.
Whether there is a difference in long-term outcomes
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Figure 4 Decision guide for compromised patients.
(A) Resection extent; (B) SBRT/ablation vs. VATS surgery. Decision guide for a compromised patient with a typical stage I lung cancer. The
reference (for improvement or worsening) is the treatment in parentheses.
a

, data not parsed by resection extent (segment vs. wedge).

Δ FEV1, change in FEV1 ≥6 months; Abl, ablation (any thermal technique); Conf, confidence in the evidence; FFR, freedom from
recurrence (only recurrence counts as an event); LCSS, lung cancer specific survival (only a death due to lung cancer counts as an event);
L, lobectomy; LR-FFR, locoregional freedom from recurrence; NSCLC, non-small cell lung cancer; OS, overall survival; PFT, pulmonary
function tests; QOL, quality of life; SBRT, stereotactic body radiotherapy; SL, sublobar resection; Seg, segmentectomy; VATS, videoassisted thoracic surgery; W, wedge.
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Table 4 Key takeaway points with limited pulmonary reserve
• Surgery with good short- and long-term outcomes is feasible in patients with severe pulmonary compromise when carefully selected
• VATS markedly ameliorates 90-day morbidity and mortality over thoracotomy
• There is no clear difference in short- and long-term outcomes between sublobar resection vs. lobectomy
• Resection extent is determined primarily by physiologic, anatomic and technical factors
• SBRT has the least short-term toxicity but some risk of late toxicity
• Ablation may have higher short-term toxicity than SBRT, but little risk of long-term toxicity
• Increasing compromise appears to proportionally increase morbidity/toxicity of all modalities
• Treatment selection (SBRT, ablation, surgery) should be individualized, key drivers are:
• How the patient weighs acute vs. intermediate toxicity and long-term outcomes
• Anticipated morbidity/mortality for each treatment option for the individual patient (first short- then intermediate-term)
• Long-term OS/LCSS is worse for SBRT/ablation than resection

VATS, video-assisted thoracic surgery; SBRT, stereotactic body radiotherapy; OS, overall survival; LCSS, lung cancer specific survival.

by resection extent in compromised patients is unclear
(conflicting results, few NRCs, small study sizes, residual
confounding and similar unadjusted outcomes; see Tab. S3-3
of Part 3) (7).
Selection is crucial in compromised patients, but not
well-defined. Good short- and long-term outcomes are
reported despite severely limited PFTs, but these patients
are presumably otherwise robust.
SBRT/ablation vs. surgery
Extrapolation (general evidence, older patients) suggests
meaningfully better short-term outcomes for SBRT over
surgery. This may be accentuated in more compromised
patients and slightly diminished with VATS resection, less
clearly diminished by sublobar resection.
Long-term outcomes in compromised patients are
consistently worse for SBRT vs. surgery (10–20% 5-year OS
difference; see Tab. 6 and Fig. S4-4 of Part 4) (8). However,
studies are limited and only partially adjusted. These patients
are undoubtedly carefully selected; no specific characteristics
have emerged on which to base treatment selection.
Decision guide in compromised patients
Resection extent
(I) Key outcomes
Short-, intermediate- and long-term outcomes are similar
after lesser resection vs. lobectomy (Figure 4A); key points
are summarized in Table 4. However, this applies to a
selected minority of compromised patients. The conclusion
should be that, when carefully selected, good outcomes
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can be anticipated even in compromised patients. The key
driver is patient selection.
(II) Effect modifiers
The benefit of VATS increases with greater degrees of
compromise (for all types of resection).
(III) Selection and patient preferences
How to select patients for resection is poorly defined.
Supported rationale suggests that patients selected for
surgery have characteristics that counter a “compromised”
categorization—e.g., good PS, normal daily activities, good
cardiopulmonary exercise test performance.
Supported rationale suggests anatomic and physiologic
factors drive selection of the type of resection. Resection
of a non-functioning lobe (e.g., with severe emphysema)
may even improve pulmonary function. Anatomic location
impacts the feasibility of segment or wedge resection with
adequate margins. Technical factors are important—a
straightforward lobectomy or large wedge may be better
than a complex segmentectomy.
These physiologic, anatomic and technical considerations
generally overshadow patient preferences.
SBRT/ablation vs. surgery
(I) Key outcomes
In compromised patients, short-term outcome differences
become prominent and long-term differences are
diminished relative to healthy patients (Figure 4B). SBRT
has clear short-term advantages over surgery (less so for
ablation) but worse long-term outcomes (low-confidence
evidence). PFTs and QOL are similar after SBRT/ablation
vs. VATS resection (indirect evidence).
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Figure 5 Decision guide for patients with favorable tumor characteristics.
(A) Resection extent; (B) SBRT/ablation vs. VATS surgery. Decision guide for a patient with a stage I lung cancer with favorable tumor
characteristics. The reference (for improvement or worsening) is the treatment in parentheses.
Δ FEV1, change in FEV1 ≥6 months; Abl, ablation (any thermal technique); betw, between; Conf, confidence in the evidence; FFR, freedom
from recurrence (only recurrence counts as an event); GG, ground glass; GGN, ground glass nodule; LCSS, lung cancer specific survival (only
a death due to lung cancer counts as an event); L or Lobe, lobectomy; LR-FFR, locoregional freedom from recurrence; NSCLC, non-small
cell lung cancer; OS, overall survival; PET, positron emission tomography; QOL, quality of life; SBRT, stereotactic body radiotherapy; SL,
sublobar resection; Seg, segmentectomy; VATS, video-assisted thoracic surgery; W, wedge.
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Table 5 Key takeaway points with potentially favorable tumors
• Mainly GG tumors have excellent long-term outcomes regardless of resection extent; speculation suggests this may extend to
screen-detected and low PET-avidity tumors
• Scarring after resection or SBRT/ablation may hamper the ability to identify recurrence
• Many GGNs remain stable; pure GGNs probably do not need treatment
• Small solid tumors (<1 cm) have worse long-term outcomes after sublobar resection than lobectomy, and probably after SBRT/ablation
vs. surgery
GG, ground glass; PET, positron emission tomography; SBRT, stereotactic body radiotherapy; GGN, ground glass nodule.

(II) Effect modifiers
Short- and intermediate-term outcomes increasingly favor
SBRT/ablation when surgery involves a thoracotomy
instead of VATS (Figure S1-3). Increasing degrees of
pulmonary compromise appear to proportionately increase
the morbidity/toxicity of all treatment options—i.e.,
increasing risk generally without accentuating the difference
of one modality over another.
Interstitial lung disease (ILD) is particularly challenging.
Differentiating between non-progressive interstitial
abnormalities and ILD may require specialized pulmonary
consultation. ILD is associated with limited survival, but
also a high incidence of lung cancer and death from lung
cancer—and an increased risk of SBRT toxicity.
(III) Selection and patient preferences
Individualized treatment selection is challenging; data is
limited, the time course and nature of morbidities/toxicities
of treatment modalities vary, and reported markers of a
compromised patient don’t capture actual frailty/resilience.
We propose first estimating the risk and impact of acute
morbidity/toxicity with each modality. Specific patient- or
treatment-related issues may emerge that weigh heavily—
e.g., how precariously a patient is functioning in their living
environment. SBRT generally has the least acute problems;
this is less clear for ablation. Next, consider intermediateterm morbidity/toxicity. SBRT has a low but ongoing risk of
late toxicity. It is unclear which SBRT patients experience a
decline in lung function. The patient’s valuation of an acute
risk vs. possible gradual intermediate-term impairment
is important. Finally, consider how long-term outcomes
modify the appeal of treatment options emerging from
the first steps. Long-term treatment differences have
diminished impact as competing risks of death increase.
Summary of outcomes for potentially favorable tumors
Certain tumor characteristics are presumed to correlate
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with a favorable oncologic biology, suggesting alternative
treatments over lobectomy. These include GG, screendetected, small (≤1 cm), and slow-growing or low
PET-avidity tumors. These tumors likely affect longterm oncologic outcomes; general data on short- and
intermediate-term outcomes should apply equally to
favorable tumors.
GG and screen-detected tumors have excellent longterm outcomes regardless of resection extent (see Tabs. 5,6 of
Part 3) (7). However, late recurrence (>5-year) of GG
tumors after sublobar resection may occur (20). Speculative
extrapolation suggests that tumors exhibiting low PETavidity or slow progression may also have excellent long-term
outcomes regardless of resection extent. However, outcomes
are worse after sublobar resection vs. lobectomy for small
solid tumors (<1 cm; see Tab. S3-4 and Fig. S3-6 of Part 3) (7).
No data is available on SBRT/ablation in favorable
tumor types. For <1 cm tumors rationale suggests worse
outcomes for SBRT vs. sublobar resection (considering that
small tumors are not consistently favorable, fare worse after
sublobar resection vs. lobectomy, and generally worse longterm outcomes with SBRT vs. sublobar resection).
Decision guide in patients with favorable tumors
Decision-making for tumors with favorable characteristics
centers on long-term outcomes (Figure 5A,5B); key points
are summarized in Table 5. For predominantly GG tumors,
sublobar resection is reasonable (no major benefit or
downside vs. lobectomy). Arguments for lesser resection
are the potential development of additional GG lesions,
and that a limited resection margin may have little impact.
Arguments against lesser resection are the question about
late staple line recurrence and that scarring from resection
or SBRT hamper identification of recurrence.
However, predominantly GG lesions generally don’t
warrant treatment—prospective evidence demonstrates
that most don’t progress and surveillance with delayed
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intervention if needed maintains nearly universal cure rates
(21-25). Development or growth of a solid component
>2 mm (mediastinal windows, thin-slice CT) or
consolidation >5 mm (lung windows) justifies intervention
(not growth of the GG component) (21).
Speculation suggests sublobar resection is an alternative
to lobectomy for screen-detected, low PET-avidity and
slow-growing tumors. However, confirmatory data is
unavailable and margin distance may be important. In
healthy patients, current long-term outcomes for tumors
<1 cm support lobectomy over sublobar resection; speculation
suggests an advantage for resection over SBRT.

critical, transparent and nuanced enhances decision-making
for individual patients.

Discussion

Acknowledgments

Using the decision guides

Funding: None.

The decision guides are designed to enhance judgement by
summarizing relevant evidence and uncertainties. Clinicians
should decide how relevant specific evidence categories are
for an individual (e.g., primarily older, less so compromised
patients). The guides highlight the outcomes with relevant
differences and the confidence in the evidence. Nuances,
ambiguities and particular aspects about the patient and
tumor impact the weight given to particular considerations.
The availability and expertise with interventions in the local
setting also affect decision-making. We think this summary
of available, albeit imperfect evidence enhances clinical
judgment.
Limitations
Clearly the evidence encompassed in this project leaves
uncertainty and hampers drawing definitive conclusions.
However, we are forced to make decisions in daily care;
therefore, we sought to make the most of the evidence
despite limitations. Moreover, we strove to illuminate the
weaknesses.
A limitation of the overall approach is that assessments
inherently involve a degree of subjectivity. We think this is
minimized by requiring extensive discussion and consensus
of the entire panel. Furthermore, while consistency
among studies supports attribution of an outcome to an
intervention, it can also stem from consistent residual
confounding. We think this is unlikely because we could not
find relationships to the overall degree of or to particular
domains of residual confounding.
Nevertheless, we hope that the effort to be comprehensive,
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Conclusions
Assessment of evidence for treatment options for cI
NSCLC identifies key areas (e.g., short- or long-term
outcomes) where relevant differences are manifest in various
settings. A graphic tool facilitates focusing on the key areas
and weighing multiple outcomes and uncertainties. This
promotes applying the available evidence in individualized
clinical decision-making.
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Table S1-1 Definition of a clinically meaningful difference
Variable

Units

2× meaningfully Meaningfully
worse
worse

Somewhat
Somewhat
Similar
worse
better

Meaningfully
better

↓↓↓

↓↓

↓

=

↑

↑↑

2× meaningfully
better
↑↑↑

90-day mortality

%

Δ −≥4

Δ −≥2

Δ −≥1

=

Δ +≥1

Δ +≥2

Δ +≥4

90-day grade ≥3
morbidity/toxicity

%

Δ −≥20

Δ −≥10

Δ −≥5

=

Δ +≥5

Δ +≥10

Δ +≥20

QOL (all domains)

Norm scale

Δ −≥20

Δ −≥10

Δ −≥5

=

Δ +≥5

Δ +≥10

Δ +≥20

FEV1% (pre vs. post),
healthy patient

Absol
FEV1%

Δ −≥40

Δ −≥20

Δ −≥10

=

Δ +≥10

Δ +≥20

Δ +≥40

FEV1% (pre vs. post),
severe COPD

Absol
FEV1%

Δ −≥20

Δ −≥10

Δ −≥5

=

Δ +≥5

Δ +≥10

Δ +≥20

5-year OS

%

Δ −≥20

Δ −≥10

Δ −≥5

=

Δ +≥5

Δ +≥10

Δ +≥20

5-year LCSS

%

Δ −≥20

Δ −≥10

Δ −≥5

=

Δ +≥5

Δ +≥10

Δ +≥20

FFR

%

a

Δ −≥20

Δ −≥10

Δ −≥5

=

Δ +≥5

Δ +≥10

Δ +≥20

LR FFR

%a

Δ −≥20

Δ −≥10

Δ −≥5

=

Δ +≥5

Δ +≥10

Δ +≥20

The comparison is the delta between one treatment approach and another (e.g., lobectomy vs. wedge).
a
, actuarial % at ≥2 years, if not available crude incidence.
Absol, absvolute difference in % predicted value; COPD, chronic obstructive pulmonary disease; FFR, freedom from recurrence; LCSS,
lung cancer specific survival; LR, loco-regional; Norm scale; normalized scale (0–100); pre vs. post, pre-treatment vs. ≥6 months later;
QOL, quality of life; OS, overall survival.
Process to define the threshold for a “clinically meaningful” difference: the writing panel reviewed literature, discussed potential thresholds
and arrived at a consensus at the outset for outcomes in which a formal standard is not available (1). For quality-of-life domains generally
accepted thresholds for clinically meaningful differences have been defined (2-8). For FEV1 in healthy patients it was considered that
≥80% is regarded as normal, that dyspnea on exertion is rarely noted for FEV1 ≥60%, and that most patients with lung cancer are not
engaged in high level strenuous activity. For outcomes lacking a formal standard, the panel considered a level at which a difference would
begin to factor into decision-making, taking into account the impact on a patient and uncertainties (e.g., definition of toxicity, recurrence).
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Generally Healthy Patients, cI (8

(v Lobe)
Effect Conf
Δ FEV1 ↑
+
Dyspnea ↑
+
QOL ↑↑ +
Pain
↑↑
+

SBRT

(v SL)
Effect Conf
=
0
=
0
↑↑
0
↑↑
0

ABL

(v SL)
Effect Conf
↑↑
0
↑↑
0

SBRT

ABL

NSCLC
Long-Term (5-year) Outcomes

SBRT

ABL

(v Lobe)
Effect Conf
OS
↓↓↓ +++
LCSS ↓↓↓ +
FFR
↓↓
+
LR- FFR ↓
+

(v SBRT)
Effect Conf
=
0
-

Short-Term (90-day) Outcomes
v Lobe/SL
Effect Conf
Mortality ↑↑ +++
Morbidity ↑
+
QOL
↑↑
+
Pain
↑↑
+

Ed)

SBRT / ABL v
Open Surgery

Intermediate (1-2 year) Outcomes
SBRT

th

ABL

SBRT

(v SL)
Effect Conf
↓↓ +++
↓↓
+
-

ABL

ABL

(v SL)
(v SBRT)
Effect Conf Effect Conf
↓↓↓ +
↓
+
↓↓↓ +
-

Fulcrum Position
determined by patient
values and preferences

(v SL)
(v SBRT)
Effect Conf Effect Conf
=/↑ 0
↓
0
=/↑ 0
↓
0
↑↑ Extpol
-

Legend

↑↑↑
↑↑
↑
=
↓
↓↓
↓↓↓

Effect
2x meaningful improvement
Meaningful improvement
Somewhat better
Similar
Somewhat worse
Meaningful worsening
2x meaningful worsening

Confidence in /
Consistency of Data
++++ Very High
+++ High
++ Moderate
+ Low
0 Very Low
Extpol Extrapolation

Nuances

No difference between peripheral and
central tumors, but toxicity over time with
SBRT for ultra-central tumors is a concern
Tumor size does not affect relative
differences

Figure S1-1 Decision guide for healthy patients—SBRT/ablation vs. open surgery.
Decision guide for a generally healthy patient with a typical stage I lung cancer. The reference (for improvement or worsening) is the
treatment in parentheses.
Δ FEV1, change in FEV1 ≥6 months; Abl, ablation (any thermal technique); Conf, confidence in the evidence; FFR, freedom from
recurrence (only recurrence counts as an event); LCSS, lung cancer specific survival (only a death due to lung cancer counts as an event); L,
lobectomy; LR-FFR, locoregional freedom from recurrence; NSCLC, non-small cell lung cancer; OS, overall survival; QOL, quality of life;
SBRT, stereotactic body radiotherapy; SL, sublobar resection; Seg, segmentectomy; W, wedge.
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Older Patients, cI (8

(v Lobe/SL)
Effect Conf
Δ FEV1 Dyspnea QOL
↑↑
0
Pain
↑↑
0

ABL

SBRT

NSCLC

(v Lobe/SL)
Effect Conf
OS
↓↓
+
LCSS ↓↓
+
FFR
LR- FFR -

(v SL)
(v SBRT)
Effect Conf Effect Conf
↑↑
0
=
0
↑↑
0
-

ABL

Fulcrum Position
determined by patient
values and preferences

ABL

(v SL)
(v SBRT)
Effect Conf Effect Conf
=/↑ 0
↓
0
=/↑ 0
↓
0
↑↑ Extpol
-

Long-Term (5-year) Outcomes
SBRT

ABL

Short-Term (90-day) Outcomes
(v Lobe/SL)
Effect Conf
Mortality ↑↑ ++
Morbidity ↑
+
QOL
↑↑ Extpol
Pain
↑↑ Extpol

Ed)

SBRT / ABL v
Open Surgery

Intermediate (1-2 year) Outcomes
SBRT

th

Legend

↑↑↑
↑↑
↑
=
↓
↓↓
↓↓↓

Effect
2x meaningful improvement
Meaningful improvement
Somewhat better
Similar
Somewhat worse
Meaningful worsening
2x meaningful worsening

Confidence in /
Consistency of Data
++++ Very High
+++ High
++ Moderate
+ Low
0 Very Low
Extpol Extrapolation

ABL

ABL

(v SL)
(v SBRT)
Effect Conf Effect Conf
↓↓↓ +
↓
+
↓↓↓ +
-

Nuances

Preferences affect how outcomes are weighed
↑ age (& ↑ frailty) accentuates short-term
differences, diminishes long-term differences
Aggressive tumors may accentuate long-term
differences
Key selection factors:
• Patient factors affecting 90-day outcomes;
PS/robustness probably more relevant than age

• Tumor and technical factors influencing
treatment effectiveness
• Tumor aggressiveness

Figure S1-2 Decision guide for older patients—SBRT/ablation vs. open surgery.
Decision guide for an older patient with a typical stage I lung cancer. The reference (for improvement or worsening) is the treatment in
parentheses.
Δ FEV1, change in FEV1 ≥6 months; Abl, ablation (any thermal technique); Conf, confidence in the evidence; FFR, freedom from
recurrence (only recurrence counts as an event); LCSS, lung cancer specific survival (only a death due to lung cancer counts as an event);
L, lobectomy; LR-FFR, locoregional freedom from recurrence; NSCLC, non-small cell lung cancer; OS, overall survival; PS, performance
status; QOL, quality of life; SBRT, stereotactic body radiotherapy; SL, sublobar resection; Seg, segmentectomy; W, wedge.
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Compromised Patients, cI (8 Ed) NSCLC
SBRT / ABL v
Open Surgery
th

Intermediate (1-2 year) Outcomes
SBRT

(v Lobe/SL)
Effect Conf
Δ FEV1
Dyspnea QOL
↑↑ Extpol
Pain
↑↑ Extpol

ABL

(v Lobe)
Effect Conf
OS
↓
+
LCSS
↓
+
FFR
LR- FFR -

(v SL)
(v SBRT)
Effect Conf Effect Conf
↑↑ Extpol
= Extpol
↑↑ Extpol
-

Short-Term (90-day) Outcomes
SBRT

Mortality
Morbidity
QOL
Pain

(v Lobe/SL)
Effect Conf
↑↑↑ Extpol
↑↑ a Extpol
↑↑ a Extpol
↑↑ a Extpol

ABL

(v SL)
Effect Conf
=/↑
0
=/↑
0
↑↑ Extpol

Long-Term (5-year) Outcomes
SBRT

ABL

Fulcrum Position
determined by patient
values and preferences

ABL

(v SBRT)
Effect Conf
↓
0
↓
0
-

Legend

↑↑↑
↑↑
↑
=
↓
↓↓
↓↓↓

Effect
2x meaningful improvement
Meaningful improvement
Somewhat better
Similar
Somewhat worse
Meaningful worsening
2x meaningful worsening

Confidence in /
Consistency of Data
++++ Very High
+++ High
++ Moderate
+ Low
0 Very Low
Extpol Extrapolation

SBRT

(v SL)
Effect Conf
↓
+
↓
+
-

ABL

ABL

(v SL)
(v SBRT)
Effect Conf Effect Conf
↓↓
0
↓
0
↓↓
0
-

Nuances

Strong impact of patient preferences/values
↑ compromise appears to proportionally ↑
morbidity/toxicity of all modalities
Selection is crucial (but undefined)
Proposed process:
1. Assess risk and impact of acute toxicity
for each modality (specific treatment- &
patient-related risks, patient resilience)

2. Assess risk of delayed toxicity
3. Assess impact of long-term outcome
differences

Figure S1-3 Decision guide for compromised patients—SBRT/ablation vs. open surgery.
Decision guide for a compromised patient with a typical Stage I lung cancer. The reference (for improvement or worsening) is the treatment
in parentheses.
a

, data not parsed by resection extent (segment vs. wedge).

Δ FEV1, change in FEV1 ≥6 months; Abl, ablation (any thermal technique); Conf, confidence in the evidence; FFR, freedom from
recurrence (only recurrence counts as an event); LCSS, lung cancer specific survival (only a death due to lung cancer counts as an event); L,
lobectomy; LR-FFR, locoregional freedom from recurrence; NSCLC, non-small cell lung cancer; OS, overall survival; QOL, quality of life;
SBRT, stereotactic body radiotherapy; SL, sublobar resection; Seg, segmentectomy; W, wedge.
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Appendix 1-1 PICO questions
Primary study questions, PICO format (population, intervention, comparator, outcomes)
Study characteristic

Inclusion criteria

Exclusion criteria

1. What are the short-term outcomes in patients with cIA NSCLC undergoing lobectomy compared to either segmentectomy or wedge
resection?
Population

Patients with cIAa NSCLC (treatment naïve)

Not NSCLC, not cIAa, not resected, other
outcomes

Interventions

Lobectomy (VATS or open)

Comparators

Segmentectomy, wedge resection, sublobar resection
(VATS or open)

Outcomes

Short-term mortality, morbidity, pain, QOL

Study design

RCT, adjusted NRC, guidelines, systematic reviews and Not meeting study design criteria
meta-analyses; observational studies if RCT or NRC not
available

2. What are the long-term outcomes in patients with cIA NSCLC undergoing lobectomy compared to either segmentectomy or wedge
resection?
Population

Patients with cIAa NSCLC (treatment naïve)

Interventions

Lobectomy (VATS or open)

Comparators

Segmentectomy, wedge resection, sublobar resection
(VATS or Open)

Outcomes

OS, LCSS, FFR, LR-FFR, DFS/RFS, PFTs, pain, QOL

Study design

RCT, adjusted NRC, guideline, systematic reviews and
meta-analyses; observational studies for endpoints of
PFTs, Pain, QOL

Not NSCLC, not cIAa, not resected, other
outcomes

Not meeting study design criteria

3. What are the short-term outcomes in patients with cIA NSCLC undergoing SBRT compared to surgical resection (lobectomy,
segmentectomy or wedge resection)?
Population

Patients with cIAa NSCLC (treatment naïve)

Not NSCLC, not cIAa, not treated by resection
or SBRT, other outcomes

Interventions

SBRT

Comparators

Surgical resection (VATS or open, lobectomy or
sublobar)

Outcomes

Short-term mortality, toxicity/morbidity, pain, QOL

Study design

RCT, adjusted NRC, guideline, systematic reviews and Not meeting study design criteria
meta-analyses, observational studies if RCT or NRC not
available

4. What are the long-term outcomes in patients with cIA NSCLC undergoing SBRT compared to surgical resection (lobectomy,
segmentectomy or wedge resection)?
Population

Patients with cIAa NSCLC (treatment naïve)

Intervention

SBRT

Comparators

Surgical resection (VATS or open, lobectomy or
sublobar)

Outcomes

OS, LCSS, FFR, LR-FFR, DFS/RFS, PFTs, pain, QOL

Study design

RCT, adjusted NRC, guideline, systematic reviews and
meta-analyses; observational studies for endpoints of
PFTs, pain, QOL
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Not NSCLC, not cIAa, not treated by resection
or SBRT, other outcomes

Not meeting study design criteria
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5. What are the short-term outcomes in patients with cIA NSCLC undergoing Ablation compared to surgical resection (lobectomy,
segmentectomy or wedge resection)?
Population

Patients with cIAa NSCLC (treatment naïve)

Not NSCLC, not cIAa, not treated by resection
or ablation, other outcomes

Interventions

Ablation (radiofrequency, microwave, cryotherapy, other)

Comparators

Surgical resection (VATS or open, lobectomy or
sublobar)

Outcomes

Short-term mortality, toxicity/morbidity, pain, QOL

Study design

RCT, adjusted NRC, guideline, systematic reviews and Not meeting study design criteria
meta-analyses, observational studies if RCT or NRC not
available

6. What are the long-term outcomes in patients with cIA NSCLC undergoing Ablation compared to surgical resection (lobectomy,
segmentectomy or wedge resection)?
Population

Patients with cIAa NSCLC (treatment naïve)

Interventions

Ablation (radiofrequency, microwave, cryotherapy, other)

Comparators

Surgical resection (VATS or open, lobectomy or
sublobar)

Outcomes

OS, LCSS, FFR, LR-FFR, DFS/RFS, PFTs, Pain, QOL

Study design

RCT, adjusted NRC, guideline, systematic reviews and
meta-analyses; observational studies for endpoints of
PFTs, pain, QOL

Not NSCLC, not cIAa, not treated by resection
or ablation, other outcomes

Not meeting study design criteria

7. What are the short-term outcomes in patients with cIA NSCLC undergoing Ablation compared to SBRT?
Population

Patients with cIAa NSCLC (treatment naïve)

Not NSCLC, not cIAa, not treated by SBRT or
ablation, other outcomes

Interventions

Ablation (radiofrequency, microwave, cryotherapy, other)

Comparators

SBRT

Outcomes

Short-term mortality, toxicity/morbidity, pain, QOL

Study design

RCT, adjusted NRC, Guideline, systematic reviews and Not meeting study design criteria
meta-analyses, observational studies if RCT or NRC not
available

8. What are the long-term outcomes in patients with cIA NSCLC undergoing Ablation compared to SBRT?
Population

Patients with cIAa NSCLC (treatment naïve)

Interventions

Ablation (radiofrequency, microwave, cryotherapy, other)

Comparators

SBRT

Outcomes

OS, LCSS, FFR, LR-FFR, DFS/RFS, PFTs, pain, QOL

Study design

RCT, adjusted NRC, guideline, systematic reviews and
meta-analyses; observational studies for endpoints of
PFTs, Pain, QOL

Not NSCLC, not cIAa, not treated by SBRT or
ablation, other outcomes

Not meeting study design criteria

a

, inclusion of stage II–IIIA allowed if included together with stage I; stage translated into 8th edition nomenclature as much as possible for
consistency across studies and contemporary applicability.
DFS/RFS, disease/recurrence-free-survival; FFR, freedom-from-recurrence; LCSS, lung cancer specific survival; LR, loco-regional; NRC,
non-randomized comparison; NSCLC, non-small cell lung cancer; OS, overall survival; PFT, pulmonary function tests; QOL, quality-of-life;
RCT, randomized controlled trial; SBRT, stereotactic body radiotherapy; VATS, video-assisted thoracic surgery.
No formal study protocol was written beyond the PICO questions. This systematic review was not registered as such.
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Appendix 1-2 Search strategies and results
For all Searches:
Source: PubMed
Filters: English, 2000-2021, journal article
Initial Formal Searches: December 2020
initial Ad Hoc searches: May 2020 to May 2021
Date of Last formal update search: October 7, 2021
Date of Last Ad Hoc update searches: October 2021
Contacts with authors regarding details or ongoing studies:
STEPS – Wentao Fang, Shanghai, China & Jun Wang, Beijing 4-23-2020
CALGB 140503 Nassar Altorki, NY, USA 4-27-2020
JCOG 1211 Kenji Suzuki, Japan 2-24-2020
Yasuhiro Tsutani, Hiroshima, Japan 2-20-2020
Additional information
Further detail (full search lists, reasons for exclusion, etc.) can be provided by contacting the corresponding author.

Screening

Targeted Search (specific to context and topic)
or Identified by review of reference lists
(n=317)

Records screened after duplicates removed
(n=1,954)

Eligibility

Records identified through
database searching
(n=1,802)

Full-text articles assessed for eligibility
(n=407)

Included

Identification

Resection extent

Studies included in overall synthesis
(n=267)

Records excluded
(n=1,547)

Full-text articles excluded, with reasons
(n=140)
No Adjustment or <50 patients per arm
Does not fit specific table criteria (e.g.,
size/date)
No comparator or incompatible analysis/
outcomes/format
Review Article
Flawed statistical analysis
Tangential or overly specific question

36
17
28
33
1
25

Search string
("carcinoma, non small cell lung"[MeSH Terms] OR ("carcinoma non small cell lung"[All Fields] OR "carcinomas non small cell lung"[All
Fields] OR "lung carcinoma non small cell"[All Fields] OR "lung carcinomas non small cell"[All Fields] OR "Non-Small-Cell Lung
Carcinomas"[All Fields] OR "Nonsmall Cell Lung Cancer"[All Fields] OR "non-small-cell lung carcinoma"[All Fields] OR "non small cell
lung carcinoma"[All Fields] OR "carcinoma non small cell lung"[All Fields] OR "Non-Small Cell Lung Cancer"[All Fields])) AND(“early
stage” OR “stage1” OR “stage Ia”)AND ("Pneumonectomy"[MeSH Terms] OR ("lobectom*"[All Fields] OR "pneumonectom*"[All
Fields])) AND ("sublobar resection*"[Title/Abstract] OR "wedge resection*"[Title/Abstract] OR "segmentectom*"[Title/Abstract] OR
"segment resection*"[Title/Abstract]).
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Screening

Targeted Search (specific to context and topic)
or Identified by review of reference lists
(n=61)

Records screened after duplicates removed
(n=1,157)

Eligibility

Records identified through
database searching
(n=1,106)

Full-text articles assessed for eligibility
(n=92)

Included

Identification

Quality of life

Studies included in overall synthesis
(n=69)

Records excluded
(n=1,065)

Full-text articles excluded, with reasons
(n=23)
No Adjustment or <50 patients per arm
Does not fit specific table criteria (e.g.,
size/date)
Incompatible analysis
No QOL tool used
No baseline/pre-op assessment
Not specific to an intervention
Review Article

3
9
10

1

Search string: QOL review:
("carcinoma, non small cell lung"[MeSH Terms] OR "carcinoma non small cell lung"[All Fields] OR "carcinomas non small cell lung"[All
Fields] OR "lung carcinoma non small cell"[All Fields] OR "lung carcinomas non small cell"[All Fields] OR "Non-Small-Cell Lung
Carcinomas"[All Fields] OR "Nonsmall Cell Lung Cancer"[All Fields] OR "non-small-cell lung carcinoma"[All Fields] OR "non-smallcell lung carcinoma"[All Fields] OR "carcinoma non small cell lung"[All Fields] OR "Non-Small Cell Lung Cancer"[All Fields] AND
((journalarticle[Filter]) AND (english[Filter]))) OR (lung neoplasm[MeSH Terms]) AND ((("quality of life") OR ("qol")) OR ("pain"))
OR (quality of life[MeSH Terms]) AND ((journalarticle[Filter]) AND (english[Filter])) AND (("ablation"[All Fields] OR "radiofrequency
ablation"[All Fields] OR "radiofrequency ablation"[MeSH Terms] OR "catheter ablation"[MeSH Terms] OR "catheter ablation"[MeSH
Terms] OR "catheter ablation"[MeSH Terms]) OR ("radiosurgery"[All Fields] OR "radiosurgery"[MeSH Terms] OR "SBRT"[All Fields]
OR "Stereotactic body radiation therapy"[All Fields] OR "stereotactic radiosurgery"[All Fields]) OR ((("Pneumonectomy"[MeSH Terms]
OR ("lobectom*"[All Fields] OR "pneumonectom*"[All Fields])) OR ("sublobar resection*"[Title/Abstract] OR "wedge resection*"[Title/
Abstract] OR "segmentectom*"[Title/Abstract] OR "segment resection*"[Title/Abstract])).
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Screening

Targeted Search (specific to context and topic)
or Identified by review of reference lists
(n=142)

Records screened after duplicates removed
(n=1,124)

Eligibility

Records identified through
database searching
(n=1,063)

Full-text articles assessed for eligibility
(n=186)

Included

Identification

SBRT

Studies included in overall synthesis
(n=133)

Records excluded
(n=938)

Full-text articles excluded, with reasons
(n=53)
No Adjustment or <50 patients per arm
10
No comparator or incompatible analysis/ 26
outcomes/format
Review Article
15
Flawed statistical analysis
1
Tangential or overly specific question
1

Search string: SBRT review:
"carcinoma, non small cell lung"[MeSH Terms] OR "carcinoma non small cell lung"[All Fields] OR "carcinomas non small cell lung"[All
Fields] OR "lung carcinoma non small cell"[All Fields] OR "lung carcinomas non small cell"[All Fields] OR "Non-Small-Cell Lung
Carcinomas"[All Fields] OR "Nonsmall Cell Lung Cancer"[All Fields] OR "non-small-cell lung carcinoma"[All Fields] OR "non-smallcell lung carcinoma"[All Fields] OR "carcinoma non small cell lung"[All Fields] OR "Non-Small Cell Lung Cancer"[All Fields] AND "early
stage"[All Fields] OR "stage1"[All Fields] OR "stage 1"[All Fields] OR "stage I"[All Fields] OR "stage Ia"[All Fields] OR "stage Ib"[All
Fields] OR "ct1n0"[All Fields] OR "ct1a*"[All Fields] OR "ct1b*"[All Fields] OR "cTI"[All Fields] OR "cTIa"[All Fields] OR "cTIb"[All
Fields] AND ("radiosurgery"[All Fields] OR "radiosurgery"[MeSH Terms] OR "SBRT"[All Fields] OR "Stereotactic body radiation
therapy"[All Fields] OR "stereotactic radiosurgery"[All Fields]) AND ("journal article"[Publication Type] AND "english"[Language]) AND
("journal article"[Publication Type] AND "english"[Language]).
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Screening

Targeted Search (specific to context and topic)
or Identified by review of reference lists
(n=29)

Records screened after duplicates removed
(n=173)

Eligibility

Records identified through
database searching
(n=162)

Full-text articles assessed for eligibility
(n=40)

Included

Identification

Ablation

Studies included in overall synthesis
(n=27)

Records excluded
(n=133)

Full-text articles excluded, with reasons
(n=13)
No Adjustment or <50 patients per arm
No comparator or incompatible analysis/
outcomes/format
Review Article
Tangential or overly specific question

7
1
4
1

Search string: ablation review:
"carcinoma, non small cell lung"[MeSH Terms] OR "carcinoma non small cell lung"[All Fields] OR "carcinomas non small cell lung"[All
Fields] OR "lung carcinoma non small cell"[All Fields] OR "lung carcinomas non small cell"[All Fields] OR "Non-Small-Cell Lung
Carcinomas"[All Fields] OR "Nonsmall Cell Lung Cancer"[All Fields] OR "non-small-cell lung carcinoma"[All Fields] OR "non-smallcell lung carcinoma"[All Fields] OR "carcinoma non small cell lung"[All Fields] OR "Non-Small Cell Lung Cancer"[All Fields] AND "early
stage"[All Fields] OR "stage1"[All Fields] OR "stage 1"[All Fields] OR "stage I"[All Fields] OR "stage Ia"[All Fields] OR "stage Ib"[All
Fields] OR "ct1n0"[All Fields] OR "ct1a*"[All Fields] OR "ct1b*"[All Fields] OR "cTI"[All Fields] OR "cTIa"[All Fields] OR "cTIb"[All
Fields] AND "ablation"[All Fields] OR "radiofrequency ablation"[All Fields] OR "radiofrequency ablation"[MeSH Terms] OR "catheter
ablation"[MeSH Terms] OR "catheter ablation"[MeSH Terms] OR "catheter ablation"[MeSH Terms] Journal Article, English (2000-2020).
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